IMI2 - Call 21

Development of antivirals as well as other types of therapeutics to address a rapid response to the current COVID-19 outbreak; therapeutics to address the current and/or future coronavirus outbreaks; diagnostics, ensuring rapid evaluation of candidates based on existing technologies;
fast and reliable tools that go beyond the state of the art for detection of COVID-19 carriers and symptomatic individuals suspected of COVID-19 infection.

Agency or Funder
Eligibility (if available)

See funding call for eligibility rules

Date of announcement
Date application deadline